BRPI0922788A2 - Composição para o crescimento de culturas virais, métodos de aumento da taxa de crescimento viral e da placa de cultura viral e de redução do tempo de atraso de crescimento de cultura viral e kit para cultura de vírus - Google Patents

Composição para o crescimento de culturas virais, métodos de aumento da taxa de crescimento viral e da placa de cultura viral e de redução do tempo de atraso de crescimento de cultura viral e kit para cultura de vírus

Info

Publication number
BRPI0922788A2
BRPI0922788A2 BRPI0922788-1A BRPI0922788A BRPI0922788A2 BR PI0922788 A2 BRPI0922788 A2 BR PI0922788A2 BR PI0922788 A BRPI0922788 A BR PI0922788A BR PI0922788 A2 BRPI0922788 A2 BR PI0922788A2
Authority
BR
Brazil
Prior art keywords
viral
culture
growth
composition
methods
Prior art date
Application number
BRPI0922788-1A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jill A Livengood
O'neil Wiggan
Richard Kinney
Jorge Osorio
Original Assignee
Inviragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inviragen Inc filed Critical Inviragen Inc
Priority to BR122020015754A priority Critical patent/BR122020015754B8/pt
Publication of BRPI0922788A2 publication Critical patent/BRPI0922788A2/pt
Publication of BRPI0922788A8 publication Critical patent/BRPI0922788A8/pt
Publication of BRPI0922788B1 publication Critical patent/BRPI0922788B1/pt
Publication of BRPI0922788B8 publication Critical patent/BRPI0922788B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
BRPI0922788A 2008-12-05 2009-12-04 composição para uso no crescimento de culturas virais e kit para cultura de vírus BRPI0922788B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020015754A BR122020015754B8 (pt) 2008-12-05 2009-12-04 métodos para aumentar a taxa de crescimento viral, para aumentar o tamanho da placa de uma cultura viral, para reduzir o tempo de latência do crescimento de uma cultura viral, e para a cultura de vírus para a produção e fabricação

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12026208P 2008-12-05 2008-12-05
US61/120,262 2008-12-05
PCT/US2009/066848 WO2010065911A1 (en) 2008-12-05 2009-12-04 Compositions, methods and uses for inducing viral growth

Publications (4)

Publication Number Publication Date
BRPI0922788A2 true BRPI0922788A2 (pt) 2015-08-18
BRPI0922788A8 BRPI0922788A8 (pt) 2017-12-12
BRPI0922788B1 BRPI0922788B1 (pt) 2021-03-23
BRPI0922788B8 BRPI0922788B8 (pt) 2021-05-25

Family

ID=42231513

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0922788A BRPI0922788B8 (pt) 2008-12-05 2009-12-04 composição para uso no crescimento de culturas virais e kit para cultura de vírus
BR122020015754A BR122020015754B8 (pt) 2008-12-05 2009-12-04 métodos para aumentar a taxa de crescimento viral, para aumentar o tamanho da placa de uma cultura viral, para reduzir o tempo de latência do crescimento de uma cultura viral, e para a cultura de vírus para a produção e fabricação

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020015754A BR122020015754B8 (pt) 2008-12-05 2009-12-04 métodos para aumentar a taxa de crescimento viral, para aumentar o tamanho da placa de uma cultura viral, para reduzir o tempo de latência do crescimento de uma cultura viral, e para a cultura de vírus para a produção e fabricação

Country Status (20)

Country Link
US (3) US8871487B2 (pt)
EP (1) EP2366024B1 (pt)
JP (2) JP5728742B2 (pt)
KR (1) KR101784951B1 (pt)
CN (2) CN105219734B (pt)
AR (1) AR074483A1 (pt)
AU (1) AU2009322175B2 (pt)
BR (2) BRPI0922788B8 (pt)
CA (1) CA2745962C (pt)
CO (1) CO6390063A2 (pt)
CU (1) CU20110128A7 (pt)
HR (1) HRP20191324T1 (pt)
IL (2) IL213389B (pt)
MX (2) MX2011005886A (pt)
MY (1) MY178195A (pt)
NZ (1) NZ593415A (pt)
SG (3) SG10202007719TA (pt)
TW (2) TWI461536B (pt)
WO (1) WO2010065911A1 (pt)
ZA (3) ZA201104364B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009322175B2 (en) * 2008-12-05 2014-10-09 Takeda Vaccines, Inc. Compositions, methods and uses for inducing viral growth
EP2746386A1 (en) * 2012-12-21 2014-06-25 Lonza Cologne GmbH Materials and methods for cell culture
JP6780638B2 (ja) * 2015-03-30 2020-11-04 味の素株式会社 ヒト血清アルブミンを含む神経幹細胞増殖培地
CA3194032A1 (en) * 2020-09-04 2022-03-10 The University Of Chicago Materials and methods of treating viral infection with amphiphilic block copolymers
WO2023147342A2 (en) * 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
EP4626574A1 (en) * 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
AU4330597A (en) * 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
MY150893A (en) * 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP1218382B1 (de) 1999-10-08 2004-01-28 Grünenthal GmbH Bicyclische imidazo-3-yl-aminderivate
ATE526411T1 (de) * 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
AU2003205169A1 (en) * 2002-01-15 2003-07-30 Acambis, Inc. Viral vaccine production method
EP1492890A4 (en) * 2002-03-29 2006-10-18 Merck & Co Inc EXPLOSIVE PROCEDURE FOR THE PRODUCTION OF ADENOVIRUS AND ADENOVIRUS STEM MIXTURES
RU2237065C2 (ru) 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
PL199642B1 (pl) * 2002-11-15 2008-10-31 Inst Immunologii I Terapii Do Preparat bakteriofagowy o podwyższonej trwałości oraz zastosowanie blokowego kopolimeru tlenku etylenu i tlenku propylenu
US20100068147A1 (en) * 2006-10-05 2010-03-18 Agency for Science , Technology and Research Dengue diagnosis and treatment
WO2009014774A1 (en) * 2007-04-06 2009-01-29 Inviragen, Inc. Methods and compositions for live attenuated viruses
US8367370B2 (en) * 2008-02-11 2013-02-05 Wheeler Aaron R Droplet-based cell culture and cell assays using digital microfluidics
AU2009322175B2 (en) 2008-12-05 2014-10-09 Takeda Vaccines, Inc. Compositions, methods and uses for inducing viral growth

Also Published As

Publication number Publication date
TWI573874B (zh) 2017-03-11
ZA201104364B (en) 2022-10-26
ZA201600550B (en) 2021-08-25
AU2009322175B2 (en) 2014-10-09
BR122020015754B1 (pt) 2021-03-23
CN105219734A (zh) 2016-01-06
JP6174066B2 (ja) 2017-08-02
IL238819A0 (en) 2015-06-30
WO2010065911A1 (en) 2010-06-10
CU20110128A7 (es) 2012-06-21
AU2009322175A1 (en) 2011-06-30
EP2366024B1 (en) 2019-05-01
CN102272294B (zh) 2015-09-02
US20150010983A1 (en) 2015-01-08
MX2011005886A (es) 2011-07-28
BRPI0922788B8 (pt) 2021-05-25
CA2745962A1 (en) 2010-06-10
US20180251737A1 (en) 2018-09-06
EP2366024A4 (en) 2012-07-04
EP2366024A1 (en) 2011-09-21
IL213389A0 (en) 2011-07-31
IL213389B (en) 2018-10-31
JP2015109874A (ja) 2015-06-18
TW201514302A (zh) 2015-04-16
NZ593415A (en) 2014-04-30
AR074483A1 (es) 2011-01-19
CN105219734B (zh) 2020-03-03
JP2012510822A (ja) 2012-05-17
SG10202007719TA (en) 2020-09-29
MY178195A (en) 2020-10-06
KR101784951B1 (ko) 2017-10-12
TW201030148A (en) 2010-08-16
BR122020015754B8 (pt) 2021-04-06
BRPI0922788B1 (pt) 2021-03-23
US8871487B2 (en) 2014-10-28
BRPI0922788A8 (pt) 2017-12-12
SG10201503671TA (en) 2015-06-29
KR20110127117A (ko) 2011-11-24
CA2745962C (en) 2018-11-27
JP5728742B2 (ja) 2015-06-03
US20100144015A1 (en) 2010-06-10
CN102272294A (zh) 2011-12-07
CO6390063A2 (es) 2012-02-29
IL238819A (en) 2017-08-31
ZA202106453B (en) 2025-01-29
US9890362B2 (en) 2018-02-13
SG171972A1 (en) 2011-07-28
HRP20191324T1 (hr) 2019-10-18
MX353602B (es) 2018-01-19
TWI461536B (zh) 2014-11-21

Similar Documents

Publication Publication Date Title
BRPI0919252A2 (pt) Métodos para cultivar células, propagação e purificação de vírus
BRPI0814939A2 (pt) Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
PT2963031T (pt) Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
PT2144998T (pt) Métodos e composições para vírus vivos atenuados
GB2471806B (en) Compositions and methods for treating viral infections
SMT201600388B (it) Ligandi leganti opsina, composizioni e metodi d'uso
BR112012002137A2 (pt) método para um polipeptídeo e/ou vírus de interesse em uma cultura de célula contínua,e, composição
BRPI0908033A2 (pt) Método placas de superfície modificada e composições para adesão, cultura e desprendimento de célula
DK2331109T3 (da) Fremgangsmåder og sammensætninger til behandling af knogledefekter med placentale cellepopulationer
BRPI1006141A2 (pt) composições de anticorpo modificado, métodos para preparar e usar as mesmas
WO2011056650A9 (en) Methods and compositions for treating and preventing viral infections
BRPI0809655A2 (pt) Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
DK3199165T3 (da) Fremgangsmåder og sammensætninger til specifik hæmning af kras med asymmetrisk dobbeltstrenget rna
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
DK2279263T3 (da) Rnase-h-baserede assays med anvendelse af modificerede rna-monomerer
BRPI0816130A2 (pt) Métodos para a fabricação de uma preparação e para aumentar a resistência a uma infecção viral em um indivíduo.
BRPI0908240A2 (pt) inibidores do vírus da hepatite c
BRPI0907733A2 (pt) Inibidores do vírus da hepatite c
BRPI0922788A2 (pt) Composição para o crescimento de culturas virais, métodos de aumento da taxa de crescimento viral e da placa de cultura viral e de redução do tempo de atraso de crescimento de cultura viral e kit para cultura de vírus
EP2349296A4 (en) SYNTHETIC ONCOLYTIC VIRAL SYMBIOSIS OBTAINED BY GENETIC ENGINEERING
BRPI0911176A2 (pt) Métodos de extinção melhorados para inativação de patógeno de células vermelhas sanguíneas
BR112013005077A2 (pt) método de quantificação de dna genômico residual, kit para quantificar dna genômico residual e uso do kit um pcr quantitativo em tempo real
EP1984323A4 (en) VIRAL POLYMERASE INHIBITORS
EP2294192A4 (en) COMPOSITIONS AND METHODS OF TREATMENT AND VACCINATION AGAINST DENGUE VIRUS (DV)
BR112013010738A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção viral

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/120,262 DE 05/12/2008 REIVINDICADA NO PCT/US2009/066848, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DE ENTRADA NA FASE NACIONAL SER DISTINTO DAQUELE QUE DEPOSITOU O PEDIDO ANTERIOR CUJA PRIORIDADE E REIVINDICADA E APRESENTOU COPIA DO CORRESPONDENTE DOCUMENTO DE CESSAO EM 27/12/2011, CONTUDO O PRAZO PARA A APRESENTACAO DA CESSAO DO DIREITO DE PRIORIDADE EXPIRAVA EM 05/08/2011 (60 DIAS APOS O DEPOSITO DE ENTRADA DA FASE NACIONAL DO BRASIL), CONFORME AS DISPOSICOES PREVISTAS NA

B25C Requirement related to requested transfer of rights

Owner name: INVIRAGEN, INC. (US)

B25A Requested transfer of rights approved

Owner name: TAKEDA VACCINES, INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: TAKEDA VACCINES, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF